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Simple Summary: Feline chronic gingivostomatitis (FCGS) is a chronic, painful, oral inflammatory
disease, which can be associated with retroviral disease comorbidity’s, namely feline immunode-
ficiency virus (FIV) and feline leukaemia virus (FeLV). A total 111 case series of cats affected by
this oral disease, treated with dental extractions, were analyzed retrospectively, considering if they
carried or not one of these retroviral diseases. Cats with lingual ulcers, independently from their
retroviral status, were 2.7 times more prone to have a worse response to dental extractions than
cats without lingual ulcers. When compared with cats without retroviral disease, FeLV-positive cats
presented less proliferative lesions and tended to have more lingual ulcers. Furthermore, these cats
had a significantly worse outcome, with 7.5 times more chances of having no improvement.
Abstract: This study aims to evaluate and compare the clinical outcome after dental extractions
of cats with FCGS infected with feline immunodeficiency virus (FIV) and feline leukaemia virus
(FeLV). A retrospective case series included cats with diagnosis of FCGS, availability of detailed
clinical records, full-mouth dental radiographs, and retroviral disease test results. Effectiveness
of surgical treatment (EOT) was registered. Three groups were defined: control, FIV and FeLV. In
this study, 111 cats were included: 60 controls, 29 FIV- and 22 FeLV-positive cats. When compared
with control cases, FeLV-positive cats had significantly less proliferative stomatitis lesions, and they
tended to have more lingual ulcers. Concurrently, FeLV-positive cats had significantly less tooth
resorptive lesions. No other significant differences in FCGS clinical signs were found between groups.
FeLV-positive cats had a significantly worse outcome after dental extractions compared to the other
groups. In fact, FeLV-positive cats had 7.5 times more chances of having no improvement after dental
extractions. This study concludes that the response to dental extractions in FeLV-positive cats is
significantly worse, when comparing to cats that do not carry retroviral disease. Therefore, it is
important to acknowledge the effect of FeLV status on the prognosis of these cats.
Keywords: feline chronic gingivostomatitis; feline immunodeficiency virus; feline leukaemia virus;
dental extractions; postsurgical outcome
1. Introduction
Feline chronic gingivostomatitis (FCGS) is a painful oral inflammatory disease, which
can lead to severe malnutrition and dehydration in critical cases [1–5]. Reported prevalence
in 4858 cats, during a 12-week period, was 0.7%, in North West England first opinion
practices [5]. FCGS lesions present typically as ulcerative and/or proliferative lesions
characterized by a symmetrical and bilateral pattern, of friable consistency, bleeding easily
when manipulated [2,6–8]. Histopathological results show a lymphoplasmacytic infiltrate,
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indicative of the chronic inflammatory process. Polyclonal hypergammaglobulinemia is
also a consistent finding [1,6,7,9–12].
FCGS is considered multifactorial, although recent evidence suggests a T-cell dis-
function [12], related to infectious and non-infectious causes, such as viruses, dental
plaque, hypersensitivity reactions, environment conditions and stress in multi-cat house-
holds [6–8,13–19]. With regards to viral agents, feline calicivirus (FCV) appears to carry out
a relevant role in FCGS, three times more prevalent in these animals when compared to the
general cat population [2,15]. However, studies have not been able to consistently prove
that chronic infection by FCV is directly implicated in the pathogenesis of FCGS [2,8,13,14].
Treatment response and long-term effectiveness in all FCGS cases is still inconsis-
tent [2,9]. Its main goal is to reduce oral inflammation and antigen load, to re-establish
the oral balance and to reduce pain [2]. The main treatment strategies are surgical and
medical, often combined. The first one has demonstrated the best long-term outcome, with
full-mouth (FME) or partial-mouth extractions (PME) when including premolar and molar
teeth only [2,20]. Approximately 80% of the cats submitted to dental extractions, FME or
PME, obtained significant improvement, with some achieving complete remission of the
clinical signs, with or without the need for combined medical treatment [21–23].
Considering FCGS’s strong immune-mediated basis, medical approaches have mainly
consisted of drugs with immunosuppressive and/or immunomodulatory properties,
namely glucocorticoids [2,24–27], cyclosporine [26–30] and feline recombinant interferon
omega [31–39]. More recently, mesenchymal stem cells were reported as a new therapeutic
approach [11,40,41].
Feline immunodeficiency virus (FIV) and feline leukaemia virus (FeLV) are two impor-
tant infectious agents in cats and are known to cause immune and inflammatory disfunc-
tion and/or immunosuppression with increased risk of opportunistic infections [35,42–44].
Their association with FCGS is still not completely elucidated, but both viruses may act as
aggravating factors [1,2,14,42,45].
It is not known whether cats carrying retroviral disease and FCGS would respond
differently to surgical treatment. Therefore, this study aims to evaluate and compare the
postsurgical outcome of FCGS patients with and without retroviral disease.
2. Materials and Methods
2.1. Study Design and Variables
This study was retrospectively designed, which included cats with diagnosis of FCGS
from 4 veterinary referring practices, followed for a minimum of 3 months, between
1 January 2010 and 30 April 2021. All cases were diagnosed and managed by one of the
authors [blinded for review], in collaboration with the referral practitioners. Selection
criteria included a complete clinical history, pre- and postoperative full-mouth dental
radiographs, and retroviral disease test results. All cases were managed under the highest
standard of good care, which included the treatment with FME or PME and adjuvant
medical support (when needed) to achieve remission of clinical signs. Informed consent
was obtained from all cat owners.
Three groups were defined: control (all cats FIV and FeLV-negative), FIV (all cats
FIV-positive but FeLV-negative) and FeLV (all cats FIV-negative but FeLV-positive). Criteria
used to assign cats into the groups was solely retroviral status. Only cats with conclusive
results (in-house and laboratory immunoassay) were included in each group. All cats
were tested or retested at the same laboratory using the same laboratory technique, to
confirm their FIV/FeLV status by Enzyme Linked Immunoabsorbent Assay (ELISA). For
FIV: ViraCHECK/FIV, Synbiotics—sensitivity ≥92.6% (95% CI 82.4–97.1) and specificity
≥99.8 (95% CI 98.8–100). For FeLV: ViraCHECK/FeLV, Synbiotics—sensitivity ≥94.9%
(95% CI 83.1–98.6) and specificity ≥98.4% (95% CI 96.8–99.2). Animals that did not comply
with inclusion criteria were excluded from the study. When needed, objective informa-
tion regarding time of FCGS diagnosis and the MTBS (medical treatment before surgery)
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performed by each animal was completed, by e-mail or phone questionnaire with the
assistant clinician.
Information from each cat included: breed; sex; reproductive status; age group at
the time of dental extractions—juvenile (<3 years), adult (≥3 to <7 years), senior (≥7 to
<10 years) and geriatric (≥10 years); date of the first dental surgery; time between FCGS
diagnosis and dental extractions: “<1 year” and “≥1 year”; outdoor access; adoption
from a cattery establishment; FIV and FeLV status; FCV status (performed using RT-PCR);
oral biopsy; lesion pattern—buccal/alveolar stomatitis, lingual ulcers, caudal stomatitis,
proliferative stomatitis, ulcerative stomatitis; and radiographic findings—tooth resorption
(TR), periodontal disease and retained roots; number of lesions “≤4” or “≥5” (buccal
stomatitis, alveolar stomatitis, lingual ulcers, caudal stomatitis, periodontal disease, re-
tained roots and/or TR); medical treatment prescribed before surgery (MTBS)—analgesic
opioids, non-steroidal anti-inflammatory drugs (NSAIDs), antiseptic oral gel, corticos-
teroids, human recombinant interferon alfa (rHuIFN-α) and feline recombinant interferon
omega (rFeIFN-ω); when applicable, the duration and dosage of corticosteroid therapy:
“<1 month”, “between 1 month and 3 months” e “>3 months”; type of dental surgery—FME
or PME, and if performed in one phase or two phases; need for medical treatment after
surgery (MTAS); occurrence of relapse of clinical signs or, for the contrary, the occurrence
of clinical cure; effectiveness of treatment (EOT) final score (at least 3 months after the
performance of dental extractions); if applicable, the date and cause of death.
Oral biopsies, when performed, at least three pieces of tissue were collected in the
most representative locations of FCGS: gingiva, caudal and vestibular mucosa. Due to
increased post-biopsy morbidity, the tongue was not biopsied.
MTBS was registered if medication was being given at least one week before surgery.
MTAS was registered if medication was given 15 days after normal postsurgical medical
treatment. It was only collected information about the need for MTAS, it was not specified
which drugs were used. Relapse cases were also registered. Relapse was considered when
clinical signs returned 2 months or more after surgery.
EOT final score (Table 1) was defined as previously described [23], determined at least
after 3 months after dental extractions. Finally, EOT score was grouped into two categories:
“no significant improvement” vs. “significant improvement or cure”, corresponding to the
grouping of EOT 0 and 1 vs. EOT 2 (a and b) and 3 (a and b).
Table 1. EOT score for FCGS surgical treatment.
EOT Score for FCGS Treatment
0 no improvement or worsening of clinical signs following FME or PME with continuing MTAS at final recheckexamination
1 little improvement with ongoing clinical signs after FME or PME and continuing MTAS at final recheck examination
2 substantial improvement with ongoing but improved clinical signs
a substantial improvement after dental surgery without the need for MTAS until final recheck examination
b substantial improvement after dental surgery, although MTAS was necessary for some finite period of time untilfinal recheck examination
3 complete resolution of clinical signs after FME or PME: clinical cure
a complete resolution following FME or PME without the need for MTAS until final recheck examination
b complete resolution following FME or PME, although MTAS was necessary for some finite period of time until finalrecheck examination
2.2. Statistical Analysis
Data registration, exploratory and descriptive analysis were performed using a com-
mercial software (IBM SPSS Statistics for Windows (2019). IBM Corp. Released 2019.
Version 26.0. Armonk, NY: IBM Corp). For inferential statistics analysis, R Software version
3.6.3 (R Core Team (2020). R: A language and environment for statistical computing. R
Foundation for Statistical Computing, Vienna, Austria) was used. Pairwise comparisons
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of groups of animals (control, FIV and FELV) were performed using Fisher’s Exact Test.
After Bonferroni correction, p ≤ 0.017 was considered statistically significant. To explore
the effects of FCGS clinical presentation (lingual ulcers, proliferative stomatitis, TR and
periodontal disease) and treatment variables (use of corticosteroids, surgery and number
of phases) in clinical response, simple and multiple binary logistic regression models were
used, considering “no significant improvement” as the event of interest. Model 1 presents
crude Odds Ratio (OR) and respective 95% Confidence Interval (IC) as a measure of as-
sociation between each independent variable and the outcome variable. In the Model 2,
the effect of the group was controlled for clinical relevant variables, whereas Model 3 was
adjusted for group and treatment variables. Nagelkerke pseudo R2 is given as indicator
of model fit. A significance level of 5% was assumed for each parameter. Finally, it was
performed a survival analysis of the three groups, by the performance of Kaplan-Meier
curves and log-rank analysis.
3. Results
3.1. Sample Characterization, Clinical and Treatment Variables
One-hundred and eleven cats were included in this study, 60 in control group, 29
in group FIV and 22 in group FeLV. Ninety-six percent (107/111) of cats were Domestic
Shorthair. The average of postoperative follow-up for control, FIV and FeLV groups was
1206 ± 890, 971 ± 572 and 866 ± 745 days, respectively. Mean age at time of tooth extraction
of control, FIV and FeLV groups was 7 ± 4, 7 ± 3 and 6 ± 3 years, respectively. Sex, age
group, outdoor access, cattery origin, neutered status, FCV results and time between
diagnosis and surgery for all groups are shown in Table 2. No differences were found
between groups for the variables mentioned. In FeLV, FIV and control groups, 9%, 10%
and 2% were not neutered cats, with no significant differences found between groups.
Table 2. General characterization of the retrospective series.
Total Control FIV FeLV
n (%) n (%) n (%) n (%) p Value
Total Sample 111 (100%) 60 (54%) 29 (26%) 22 (20%)
Sex 0.456
Female 51 (46%) 31 (52%) 11 (38%) 9 (41%)
Male 60 (54%) 29 (48%) 18 (62.1%) 13 (59%)
Age Group 0.593
Junior 12 (11%) 9 (15%) 1 (3%) 2 (9%)
Adult 51 (46%) 25 (42%) 14 (48%) 12 (55%)
Senior 24 (22%) 11 (18%) 8 (28%) 5 (23%)
Geriatric 24 (22%) 15 (25%) 6 (21%) 3 (14%)
Outdoor Access 0.295
No 17 (15%) 12 (20%) 2 (7%) 3 (14%)
Yes 94 (85%) 48 (80%) 27 (93%) 19 (86%)
Cattery (Origin) 0.592
No 78 (70%) 42 (70%) 22 (76%) 14 (64%)
Yes 33 (30%) 18 (30%) 7 (24%) 8 (36%)
Neutered 0.117
No 6 (5%) 1 (2%) 3 (10%) 2 (9%)
Yes 105 (95%) 59 (98%) 26 (90%) 20 (91%)
FCV 0.426
Not tested 73 (66%) 35 (58%) 20 (69%) 18 (82%)
Negative result 7 (6%) 4 (7%) 3 (10%) 0 (0%)
Positive result 31 (28%) 21 (35%) 6 (21%) 4 (100%)
Time between Diagnosis
and Surgery 0.134
<1 year 43 (39%) 28 (47%) 10 (34%) 5 (23%)
≥1 year 68 (61%) 32 (53%) 19 (66%) 17 (77%)
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Histopathological evaluation was performed in 40% (24/60) of cats of group control,
21% (6/29) of group FIV and in 5% (1/22) of group FeLV, all confirmed an inflammatory
lympho-plasmocytic infiltrate, typical of the chronic process.
FIV-positive cats had significantly less caudal stomatitis than cats of control group
(Table 3). Cats of group FeLV had significantly less proliferative stomatitis and less TR than
control cases. Of note, it was possible to observe that cats FeLV-positive presented more
lingual ulcers than cats of group control, although not significantly (Table 3).
Table 3. Clinical presentation and radiographic findings variables.
Total Control FIV FeLV p Value





No. of Lesions 0.147
≤4 53 (48%) 24 (40%) 15 (52%) 14 (64%) 0.364 0.080 0.569≥5 58 (52%) 36 (60%) 14 (48%) 8 (36%)
Buccal/Alveolarstomatitis 0.113
No 5 (5%) 1 (2%) 3 (10%) 1 (5%) 0.100 0.467 0.625Yes 106 (95%) 59 (98%) 26 (90%) 21 (95%)
Lingual Ulcers 0.143
No 80 (72%) 46 (77%) 22 (76%) 12 (55%) 1.000 0.061 0.140Yes 31 (28%) 14 (23%) 7 (24%) 10 (45%)
Caudal Stomatitis 0.020 #




No 59 (53%) 25 (42%) 17 (59%) 17 (77%) 0.175 0.006 * 0.233Yes 52 (47%) 35 (58%) 12 (41%) 5 (23%)
Tooth Resorption 0.022 #
No 30 (27%) 11 (18%) 8 (28%) 11 (50%) 0.408 0.010 * 0.145Yes 81 (73%) 49 (82%) 21 (72%) 11 (50%)
Periodontal Disease 0.271
No 28 (25%) 19 (32%) 5 (17%) 4 (18%) 0.205 0.278 1.000Yes 83 (75%) 41 (68%) 24 (83%) 18 (82%)
Retained Roots 0.873
No 59 (53%) 31 (52%) 15 (52%) 13 (59%) 1.000 0.622 0.777Yes 52 (47%) 29 (48%) 14 (48%) 9 (41%)
* p ≤ 0.017 was considered significant after Bonferroni correction for multiple comparisons. # p ≤ 0.05.
Medical approach prior to surgery was significantly less prescribed in cats from
group FIV than control cases (Table 4). Also, cats FeLV-positive had significantly less
oral gel as MTBS, compared to control and FIV groups (Table 4). In total, the most pre-
scribed treatment was NSAID. Corticosteroids given included methylprednisolone and
prednisolone—prescribed orally at a dosage of 1 to 2 mg/kg once a day. Methylpred-
nisolone acetate was also administered subcutaneously at the same dose, every month.
Time of corticosteroid therapy was not significantly different between groups (results not
shown). More than half of the cats in each group had received more than 3 months of
corticoid therapy before surgery—54% (15/28) in group control, 62% (8/13) in group FIV
and 64% (7/11) in group FeLV.
3.2. Response to Treatment
Time between diagnosis of FCGS and surgery was more than 1 year in 53% (32/60),
66% (19/29) and 77% (17/22) of cats of group control, FIV and FeLV, respectively. This time
interval was not significantly associated with the response to surgical treatment, for each
of the three groups (results not shown). Since the dosage was similar in all cats treated
with corticosteroids, the dose variable was not analyzed. Due to the reduced number of
cats treated with methylprednisolone acetate, analysis was not performed either. Table 5
summarizes the treatment response variables registered in this case series. MTAS and
disease relapse were not significantly different between groups.
Animals 2021, 11, 3306 6 of 13
Table 4. Treatment variables.
Total Control FIV FeLV p Value






No 6 (5%) 0 (0%) 4 (14%) 2 (9%) 0.010 * 0.070 0.688Yes 105 (95%) 60 (100%) 25 (86%) 20 (91%)
Analgesic Opioids 0.370
No 43 (39%) 20 (33%) 12 (41%) 11 (50%) 0.487 0.203 0.581Yes 68 (61%) 40 (67%) 17 (59%) 11 (50%)
NSAIDs 0.407
No 35 (32%) 16 (27%) 10 (34%) 9 (41%) 0.465 0.280 0.772Yes 76 (68%) 44 (73%) 19 (66%) 13 (59%)
Oral Gel 0.007 #
No 53 (48%) 23 (38%) 13 (45%) 17 (77%) 0.647 0.002 * 0.025 #Yes 58 (52%) 37 (62%) 16 (55%) 5 (23%)
Corticosteroids 0.905
No 57 (51%) 32 (53%) 14 (48%) 11 (50%) 0.821 0.808 1.000Yes 54 (49%) 28 (47%) 15 (52%) 11 (50%)
rHuIFN-α 0.146
No 104 (94%) 58 (97%) 25 (86%) 21 (95%) 0.085 1.000 0.375Yes 7 (6%) 2 (3%) 4 (14%) 1 (5%)
rFeIFN-ω 0.403
No 97 (87%) 52 (87%) 24 (83%) 21 (95%) 0.750 0.433 0.218Yes 14 (13%) 8 (13%) 5 (17%) 1 (5%)
Surgery 0.763
PME 53 (48%) 30 (51%) 14 (48%) 9 (41%) 1.000 0.463 0.777FME 57 (52%) 29 (49%) 15 (52%) 13 (59%)
No. of Phases 0.437
1 97 (87%) 50 (83%) 27 (93%) 20 (91%) 0.323 0.499 1.0002 14 (13%) 10 (17%) 2 (7%) 2 (9%)
* p ≤ 0.017 was considered significant after Bonferroni correction for multiple comparisons. # p ≤ 0.05.
Table 5. Response to treatment.
Total Control FIV FeLV p Value






No 58 (52%) 27 (45%) 18 (62%) 13 (59%) 0.176 0.322 1.000Yes 53 (48%) 33 (55%) 11 (38%) 9 (41%)
MTAS 0.618
No 33 (30%) 20 (33%) 8 (28%) 5 (23%) 0.634 0.426 0.756Yes 78 (70%) 40 (67%) 21 (72%) 17 (77%)
Significant
Improvement or Cure 0.002
#
No 22 (20%) 6 (10%) 6 (51%) 10 (45%) 0.194 <0.001 * 0.074Yes 89 (80%) 54 (90%) 23 (79%) 12 (55%)
* p ≤ 0.017 was considered significant after Bonferroni correction for multiple comparisons. # p ≤ 0.05.
Cats from FeLV group had significantly worst response to dental extractions when
compared to control cases. FeLV-positive cats had 7.5 times more chances of having no
improvement with dental extractions when compared to control group (Table 6). Cats with
lingual ulcers, independently of which group they were in, were 2.7 times more prone to
have a worse response to surgery than cats without lingual ulcers (Table 6).
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Improvement Model 1 Model 2 Model 3
n (%) n (%) OR (95% CI) OR (95% CI) OR (95% CI)
Group
Control 54 (90%) 6 (10%) — — —
FIV 23 (79%) 6 (21%) 2.35 (0.67–8.27) 2.69 (0.73–10.1) 2.07 (0.57–7.47)
FELV 12 (55%) 10 (45%) 7.50 (2.35–26.1) 8.61 (2.28–37.3) 6.90 (2.07–25.0)
Lingual Ulcer
No 68 (85%) 12 (15%) — —
Yes 21 (68%) 10 (32%) 2.70 (1.01–7.17) 1.94 (0.64–5.65)
Proliferative Stomatitis
No 47 (80%) 12 (20%) 1.07 (0.42–2.79) 0.68 (0.21–2.06)
Yes 42 (81%) 10 (19%) — —
Tooth Resorption
No 23 (77%) 7 (23%) 1.34 (0.46–3.61) 0.87 (0.25–2.75)
Yes 66 (81%) 15 (19%) — —
Periodontal Disease
No 22 (79%) 6 (21%) 1.14 (0.37–3.17) 1.39 (0.40–4.59)
Yes 67 (81%) 16 (19%) — —
Corticosteroids
No 49 (86%) 8 (14%) — —
Yes 40 (74%) 14 (26%) 2.14 (0.83–5.85) 2.17 (0.76–6.55)
Surgery
Partial extraction 45 (85%) 8 (15%) — —
Full extraction 43 (75%) 14 (25%) 1.83 (0.71–5.00) 1.52 (0.52–4.56)
No. of Phases
1 77 (79%) 20 (21%) 1.56 (0.38–10.5) 1.75 (0.37–12.7)
2 12 (86%) 2 (14%) — —
Nagelkerke’s Pseudo R2 0.20 0.20
Model 1: unadjusted OR; Model 2: adjusted for group and clinical variables; Model 3: adjusted for group and treatment variables;
No. = number; “No significant improvement” = EDT 0 and 1; “Significant improvement” = EDT 2 and 3.
3.3. Postsurgical Survival Analysis
Until the endpoint of data research, the percentage of deaths registered were: 27%
(16/60) at control group, 31% (9/29) at FIV group and 36% (8/22) at FeLV group. Mean
age at time of death as well as mean and median postoperative survival time are presented
in Table 7. No significant differences were found between FIV, FeLV and control Kaplan-
Meier curves (Figure 1), by log-rank analysis (p = 0.085). Excluding unknown causes of
death, main cause of death in control cases was chronic renal disease (CRD) and secondly
lymphoma. In FIV group main cause of death was also CRD and in FeLV group most cats
died with FeLV-related diseases, such as anaemia and lymphoma.
Table 7. Overall postsurgical survival time and mean age at time of death of the 111 cats with chronic
gingivostomatitis, according with retroviral disease status.
Control FIV FeLV
Median Postsurgical Survival Time (Days) 882 1425 346
Mean Postsurgical Survival Time (Days) 1291 1049 619
Mean Age at Time of Death (Years) 10.0 ± 4.2 9.6 ± 3.5 5.8 ± 3.6
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4. Discussion
The main goal of this study was to evaluate and compare the postsurgical outcome
of cats with FCGS, carrying or not retroviral disease. It was possible to identify some risk
factors associated with a worse response to dental surgery and to observe some clinical
differences, especially in FeLV-positive cats.
There was no significant difference in sex and in reproductive status distribution
between the study groups. However, according to prior studies, FIV and FeLV-positive
cats were mainly sexually intact, especially male cats, since they were more prone to carry
FIV antibodies and FeLV antigens [9,46]. These observations could be the result of an
overrepresentation of intact cats, possibly cats with outdoor access, and/or cats from a
cattery. Age average at dental extractions was similar between the three groups and to
what has been reported [23].
FCV positive status was present in more than two-thirds of the FCV-tested cases, being
highly prevalent and similar between groups. Although concurrent infection with FCV,
FeLV, and FIV has been associated with more severe oral lesions [13], co-infection with
FCV and retroviral disease was not related to an increased susceptibility to FCV infection,
since all cats had similar exposure (outdoor access and cattery origin).
It has been suggested that the sooner dental extractions are performed, the better
the postsurgical outcome for cats with FCGS [23]. However, in this study, a longer time
between diagnosis and surgical treatment was not significantly associated with a worse
outcome, with most cats being submitted to dental extractions more than one year after the
diagnosis of FCGS. This suggests some resistance from cat owners or perhaps the referring
veterinarian to accept or recommend dental extractions. Even though outdoor access and
catteries allow close contact with potentially infected cats [2,43], there were no significant
differences between cats with and without retroviral disease, regarding these variables.
With regards to clinical presentation, FIV-positive cats had significantly less caudal
stomatitis than cats without retroviral disease. Caudal stomatitis is considered a hallmark
in FCGS, but the diagnosis is based on the bilateral distribution of stomatitis lesions
extending from the alveolar to the buccal, lingual, caudal, and/or palatal mucosa, not
necessarily including all locations. The lack of caudal stomatitis lesions probably resulted
from concurrent medical treatment at time of diagnosis, especially with corticosteroids. This
fact explains the one control case and some cases with retroviral disease. In the other cases
with retroviral infection, the observation of buccal/alveolar stomatitis can represent one of
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the first signs of systemic immunodeficiency, since first lesions can be most directly related
to oral plaque. However, retroviral disease can change the evolution, distribution, and
pattern of oral lesions since the CD8+/CD4+ ratio of T cells is disturbed, especially in FIV-
infected cats [47]. Therefore, even in the absence of extension of inflammation to the caudal
mucosa, the presence of bilateral and persistent inflammatory lesions extending from
the alveolar to the buccal mucosa, associated with other chronic persistent inflammatory
lesions to the tongue and/or palatal mucosa, should also be considered FCGS.
FeLV-positive cats had significantly less proliferative stomatitis and less TR than con-
trol cases. Considering that wound healing is impaired in immunosuppressed cats [48,49],
and FeLV can infect fibroblast precursor cells and interfere with fibroblast function [50],
this could explain why oral lesions in this group are predominantly non-proliferative. The
occurrence of TR was not positively associated with cats carrying FeLV infection, which
meets the observations previously reported by other authors [51,52], where age is pointed
as the main risk factor to the development of TR in cats.
Additionally, there was a tendency for FeLV-positive cats to present more lingual
ulcers than cats without retroviral disease. Lingual inflammatory lesions are frequently
associated with FCV infection [20,23,53] but, interestingly, in this study, only 32% (10/31)
of the FCV-positive cats presented with lingual ulcers. However, due to the low number
of FCV-positive cases in the FeLV group, it was not possible to support or refute the
hypothesis that FeLV cats co-infected with FCV might have a worse clinical presentation
(with lingual ulcers) and outcome. Other authors have suggested that immunosuppression
by FeLV can lead to a predisposition and manifestation of secondary infections (by FCV,
for example) [13,42,43,54], and consequently present more frequently with lingual ulcers.
With regards to treatment variables, it was possible to notice that MTBS was signifi-
cantly less prescribed to FIV-positive cats than to cats from the control group. The same
tendency was observed for FeLV-positive cats, although not significantly. This is likely due
to a reluctance of using immunosuppressive drugs (e.g., corticosteroids or ciclosporin) in
retroviral infected cats, since these might aggravate the underlying disease. Additionally,
FeLV-positive cats had significantly less oral gel prescribed as MTBS. This may be explained
by the low number of cases in the FeLV group or due to some non-identified selection bias
from the clinician or owner, which might have limited the use of such approach. These
differences could be a result of chance, due to the limited number of cases, or could reflect
a primary difficulty from owners to topically treat these cats with the oral gel.
The variables used on the simple and multiple binary logistic regression models
were chosen, having in consideration the statistical differences between groups and their
potential role in the postsurgical outcome. Cats with lingual ulcers, independently from
their retroviral status, were 2.7 times more prone to have a worse response following dental
extractions than cats without lingual ulcers. The main goal of the surgical procedure is to
reduce the antigenic oral stimulation, by eliminating dental plaque [17,55]. It is possible
that cats with lingual ulcers remain painful after surgery and might need additional medical
treatment to reduce oral inflammation and improve tissue healing.
Given the metabolic and immunosuppressive effects of corticosteroids [24,27,56], it
should be expected that cats undergoing corticoid therapy prior to surgery, especially
those bearing retroviral disease, would have a worse postsurgical outcome because of
delayed tissue healing and increased predisposition to opportunistic infections, caused by
a potentially compromised immune response. However, no significant associations were
found between corticosteroids usage and the postoperative outcome. The interpretation of
these results should be done carefully. In all cases treated with corticosteroids, the dose
used was within the anti-inflammatory range and therefore seems to be relatively safe
in cats, independently of their retroviral status. On the other hand, because there were
no cases treated with immunosuppressive dosage of corticosteroids it was not possible
to evaluate a likely unfavorable outcome in cats with retroviral disease. Regardless, an
immunosuppressive dosage should not be advised in cats carrying retroviral disease and
its long-term usage should be avoided due to the risk of iatrogenic complications.
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In agreement with prior results [23], there was no association between FME vs. PME
or the number of phases of FME and the outcome of post-dental extractions. To the author’s
knowledge, the effect of the number of phases for FME was never evaluated. It is advocated
that FME should be done at first attempt to achieve the best chance of cure [57]. According
to the results obtained in this study, neither the number of teeth, nor the need to perform
FME at first attempt, significantly changed the outcome. This suggests that the true role
of dental plaque on FCGS aetiology is questionable, as was already proposed by other
studies [23,30].
Dental extractions resulted in significant improvement in 90% of cats without retroviral
disease, 79.3% of FIV-positive cats and 54.5% of FeLV-positive cats. The remission of FCGS
observed for control cases was superior to previously published results [20,22,23]. This
could be the result of a long-term follow-up, since most control cases were followed for
more than 2 years. Perhaps remission can be obtained in the long-term and not just due to
dental extractions alone. More studies involving the long-term follow-up of FCGS cases are
needed to understand if there are other events that might contribute to a favorable outcome.
The overall response to treatment in FCGS cats carrying retroviral disease has never
been evaluated to the author’s knowledge. FIV-positive cats seem to have no significant
difference in overall response compared to control cases. On the other hand, the response
to FCGS treatments in FeLV-positive cats was significantly worse, with 7.5 times more
chances of having no significant improvement when compared to those without retroviral
disease. Retroviral positivity does not necessarily translate into disease, especially in
FIV-positive cats, where the disease can remain latent for years without evolving into
immunodeficiency. However, dental disease and stomatitis are considered manifestations
of immunosuppression in the affected cats [47]. Therefore, we can consider that FIV and
FeLV-positive cats can potentially be affected by retroviral disease and develop FCGS. If
FCGS is just a result of immunosuppression it could be argued that FeLV-positive cats
would be at a higher risk of developing FCGS, when compared to FIV-positive cats. This
observation is also supported by the survival analysis performed in this study, since FeLV-
infected cats tended to have a shorter survival time in comparison to FIV-positive and
control cases. FeLV infection can have a relevant impact on the longevity and wellbeing of
the affected cats since it can lead to immunosuppression [47], and consequently potentiate
the occurrence of oral inflammatory lesions previously initiated by local processes [1,43,45].
Interestingly, 30% of cats in this study sample died with CRD. FCGS, similarly to
other oral chronic inflammatory diseases, can be associated with systemic manifestations,
as a consequence of the increased inflammatory burden [58], increasing the risk for CRD
secondary to immune complex glomerulonephritis [59–61]. However, because CRD is not
necessarily a consequence of oral disease and is a common cause of death in cats [62], we
cannot directly correlate, based on our results, the deaths caused by CRD with FCGS. It
would be important to perform a large cohort study of cats with FCGS, in order to evaluate
its systemic impact in the long-term, comparing to cats without oral disease.
Limitations of this study were mostly related to its retrospective nature, a long time-
frame of 10 years and a low number of cases. Additional information related to MTBS and
time to surgery was collected by veterinary inquiry. MTBS was based on the interpretation
of clinical records given by the referral clinician and therefore interpretation bias could
be a concern. Also, the time between diagnosis and surgery was a crude categorization,
which could be improved in order to obtain more accurate results. False positive or false
negative results in the retroviral and FCV tests performed could also cause bias, although
the inclusion criteria tried to include only conclusive results. Some treatments, namely
ciclosporin, interferon or even oral gel, were not extensively used in the studied population.
Therefore, their impact was not fully appreciated.
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5. Conclusions
Retroviral disease status for FeLV has a significant effect on the outcome of treat-
ment of FCGS. Therefore, it is important to acknowledge its influence in FCGS severity
and prognosis.
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